Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation". - Wikidata - wikimedia - TriplyDB

Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

http://www.wikidata.org/entity/Q34367252

about

Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects Novel immunotherapies in lymphoid malignancies Using gene therapy to manipulate the immune system in the fight against B-cell leukemias Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2d-ligands recognition PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models Smart CARs engineered for cancer immunotherapy Advances of CD19-directed chimeric antigen receptor-modified T cells in refractory/relapsed acute lymphoblastic leukemia Cytokine-Induced Killer Cells As Pharmacological Tools for Cancer Immunotherapy.5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells.From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells.A novel chimeric antigen receptor against prostate stem cell antigen mediates tumor destruction in a humanized mouse model of pancreatic cancer.Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.Local production of the chemokines CCL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma.Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.OX40 signaling is involved in the autoactivation of CD4+CD28- T cells and contributes to the pathogenesis of autoimmune arthritis.An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells.A killer choice for cancer immunotherapy.Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives.Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity Cancer Immunotherapy with Cytokine-Induced Killer Cells.Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade.Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies.The Principles of Engineering Immune Cells to Treat Cancer.Targeting Ewing sarcoma with activated and GD2-specific chimeric antigen receptor-engineered human NK cells induces upregulation of immune-inhibitory HLA-G.The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells.Analytic and Dynamic Secretory Profile of Patient-Derived Cytokine-Induced Killer Cells.Cytotoxicity of CD56-positive lymphocytes against autologous B-cell precursor acute lymphoblastic leukemia cells Current Status of Gene Engineering Cell Therapeutics.Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.T-bet promotes potent antitumor activity of CD4+ CAR T cells.CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.New developments in immunotherapy for lymphoma

P2860

Q26753082-C8007290-5135-4376-BBF5-3ABD6F3A9013 Q26777394-8D86AFD7-93FB-4068-B88C-4C921BFFD15C Q27011297-7B806AF6-C9FD-4545-AAA7-EDD8ABCC8469 Q27311035-6909500A-69F7-4B86-89DD-7796AC22BCA7 Q27339832-02C40807-9ADB-48F5-9BFD-C6BB28B444F1 Q28087236-915BA23B-D3CB-4E32-AE32-9788C94F65E2 Q33564364-E4F6AA01-4143-4AD9-8E72-440B7A5A9DD6 Q33875615-CADE4027-0FC8-4C77-9F90-A521CEFB4F96 Q33884816-3E827B41-3129-4C42-8567-C0AFC00A6F89 Q34240799-1948B034-F3A3-49FD-9A05-8E6F6020675F Q34729692-B85C6265-6A8F-4350-A003-657B874FF64E Q36123941-CC894D16-255D-47CF-A3F8-53962F8A70F1 Q36413053-58398F3A-D229-482D-94E2-440D7B1AF879 Q36413088-1EF02E1A-1AA5-4363-97EE-2BA0DFE4EB7E Q36544290-F0AD7E38-FEC1-48D9-8773-1EF92CCD6A65 Q36664207-B0F51F0C-22CF-42B0-943B-0874AC0A177B Q37588329-AAF7CC29-0FEA-4B43-86F7-84472531C4A7 Q37713476-6B8CC48C-C5D0-4AF6-9518-2F45AE9BD035 Q38199717-CE3499BA-70E7-4A1B-8FEF-05C2210CEDFC Q38208944-0BEBEE9D-4ACC-413E-AF5B-29FA62C5D9A1 Q38574526-CC870F07-4D18-46AB-BCC0-2B58BE130EF5 Q38640367-31320F5A-BB2C-471A-8947-89A3D2F309A9 Q38687547-74A211C5-257F-48D8-8480-D97C6D97C724 Q38767030-640CA779-450B-45E1-8991-048E6E1EC02C Q38782845-DD01F3FB-6D4B-4D43-9659-33780DD26FEC Q38823747-19830EF5-B1EC-4E04-B71B-462AD3278918 Q38830813-F6ADC750-096A-4C95-ACB7-5F9769E06251 Q38834059-3217E12A-A40F-4AA0-8124-333890FC51F7 Q39130457-41971D14-CF1E-4A08-BA00-4D0C6FCACE9E Q39135703-68F0886A-122E-49C8-9C0F-F40F8630762E Q40095245-93811B81-1644-448D-B283-8AAB144FCA73 Q42274903-48E01408-C8FC-46D3-9A77-CF2EE9681381 Q42556477-4EBC85A2-B3A5-4675-B56C-04A91338F1A4 Q49829282-C21A0BCB-F43A-4BCF-93E3-BA4D7A349CEB Q50531950-7236B3B3-9AE9-4DF1-AC8F-206B2757356B Q52668512-7C60C933-F072-4409-BC80-D9C017762410 Q52714322-DEC3DE9A-3CD5-4DC7-9409-0787A069530A Q58804962-63DA4AB5-079F-41B2-B0AE-F98724DF1CF3

P2860

Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

http://www.wikidata.org/entity/Q34367252

description

2013 nî lūn-bûn

@nan

2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@ast

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@en

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@nl

type

label

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@ast

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@en

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@nl

prefLabel

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@ast

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@en

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@nl

P1433

Q34367252-033A414C-9E2B-4BE2-BF7F-658C0563FDDA

P1476

Q34367252-2CE2E5A0-4470-46CE-924E-FF607D62E9E6

P2093

Q34367252-47D4E35A-287A-4096-8F29-A16690EE7450

Q34367252-893F4632-548C-4997-8B61-4003B3BEE9CD

Q34367252-EE53C957-E27B-417E-8669-989AAA17B7AD

P2860

Q34367252-0C999805-625B-4A9B-878E-B3DE28180D4B

Q34367252-0F7CB2AE-CA46-4891-85FB-6C25E5EC4C1F

Q34367252-1F051CED-273E-4E3A-A6A4-AF9D26DB5A96

Q34367252-272CAE8A-16E3-41D7-A77D-59C9661BDB7A

Q34367252-314C0C70-DDEA-4389-96BB-EEC1C7D1820C

Q34367252-429B1082-E910-4008-A076-0480AB5D43DE

Q34367252-42A2FAC5-3764-421D-B09C-F4AA178F38BD

Q34367252-42CFA51C-C01B-4613-8895-21BF33DFBECC

Q34367252-72B060A0-8284-477D-B45A-ED9B6EC25E87

Q34367252-732AC469-3C59-4317-9870-72D9AD777113

P304

Q34367252-7B9FC144-6906-4713-8B0D-070DD4EB0D64

P31

Q34367252-63B1CCF6-ACA5-4319-A20F-CDD552535F9F

P356

Q34367252-8730FB5C-11ED-471F-B440-416D3C2A2192

P433

Q34367252-2DB71705-D459-4892-B890-25A7202FFF34

P478

Q34367252-31D0C85E-F681-480F-B1C6-F52D361079F2

P577

Q34367252-70B35326-E6F7-41B7-8F53-FC027D6E09FE

P698

Q34367252-0F368CBC-58FE-4879-AB19-D527BF290211

P932

Q34367252-486382BB-A0CA-4955-85FC-D852D27EE68D

P356

P1433

Molecular Therapy

P1476

Arming cytokine-induced killer ...... CD28-OX40 "super-stimulation".

@en

P2093

Andreas A Hombach

http://www.w3.org/2001/XMLSchema#string

Gunter Rappl

http://www.w3.org/2001/XMLSchema#string

Hinrich Abken

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity.

A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells.

In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity

A retroviral vector system 'STITCH' in combination with an optimized single chain antibody chimeric receptor gene structure allows efficient gene transduction and expression in human T lymphocytes.

Less yin, more yang: confronting the barriers to cancer immunotherapy.

Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis.

Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors.

P304

2268-2277

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2013.192

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23985696

http://www.w3.org/2001/XMLSchema#string

P932

3863798

http://www.w3.org/2001/XMLSchema#string